The Latest Breaking News from Obesity

Children as young as five face a future of growing obesity, according to a new report.

Experts said the global picture represents a ‘profound tragedy and a monumental societal failure’

In many countries, buying food at supermarkets, convenience stores and online has become the norm. But what’s the convenience of modern food shopping doing to our health?

AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S.

Scientists have pinpointed and described unusual subtypes of fat cells that may help scientists explain why gut fat is linked to poor health. The research could open up new avenues for medical treatments.

Skye Bioscience is trying to establish a presence in the weight-loss drug market.

People with a high body weight living in England can now access subsidised weight-loss drugs to treat their obesity. This includes Wegovy (the weight-loss dose of Ozempic, or semaglutide) and Mounjaro (one of the brand names for tirzepatide).

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, pharmaceutical giants like Eli Lilly and Company (LLY), Novo Nordisk (NVO), and Amgen (AMGN) are betting big on next-generation weight loss treatments to dominate this booming market. Keeping reading.

‘There are a lot of people right now who want access to the medication and can’t get it’

In his latest effort to tackle rising health concerns, Prime Minister Narendra Modi has called for a nationwide movement to combat obesity and promote healthier eating habits Read further on Dynamite News:

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity treatments continue to improve